Results from the OASIS-4 study show that elinzanetant significantly reduces the frequency and severity of hot flashes in HR+ breast cancer patients – offering a potential new hormone-free treatment option.
Gilead will supply lenacapavir at no profit to up to two million people in high-incidence, low-income countries through a partnership with the Global Fund.
Bayer welcomes the U.S. Supreme Court’s decision to involve the Solicitor General in the Durnell case – a potential turning point in the glyphosate litigation.
Araris Biotech has been awarded the Strüngmann Award 2025 for its groundbreaking ADC technology – a milestone for targeted cancer therapies.
Max Zeller Söhne AG draws attention to zeller entspannung with a bold campaign centered around rare phobias. The herbal remedy is repositioned as a solution for stress and anxiety.
Torrent Pharma acquires a majority stake in JB Chemicals & Pharmaceuticals from KKR for over INR 25,000 crore and announces a subsequent merger. The deal significantly strengthens Torrent's market presence in India and globally.
From September 16–18, 2025, expopharm in Düsseldorf will bring together new exhibitors, forward-looking formats, and a strong network for the pharmacy and healthcare sector.
In 2025, marketers will increasingly rely on smart targeting and omnichannel concepts to achieve maximum impact with shrinking budgets.
BioNTech announces the full acquisition of CureVac to significantly expand its mRNA research and cancer therapy platform. The transaction strengthens Germany’s role in the global biotech landscape.
Merck drives growth in its Healthcare business with the $3.4 billion acquisition of SpringWorks Therapeutics, expanding into rare tumor therapies.
